
    
      Keratoconjunctivitis sicca (KCS) is a common multifactorial ophthalmologic disorder of the
      tears and ocular surface characterized by symptoms of burning, stinging, itching, grittiness,
      scratchiness, foreign body sensation, dryness, stickiness and tired eye sensation.

      This study is the first clinical safety and efficacy study with OTX-101 and is designed to
      compare two dose concentrations of OTX-101 against vehicle (placebo) in reducing the signs
      and symptoms of KCS and evaluate safety when dosed twice a day in both eyes over an 84 day
      period.
    
  